Market capitalization | $166.77b |
Enterprise Value | $221.08b |
PER (TTM) P/E ratio | 44.46 |
EV/FCF (TTM) EV/FCF | 31.15 |
EV/Sales (TTM) EV/Sales | 7.53 |
P/S ratio (TTM) P/S ratio | 5.68 |
P/B ratio (TTM) P/B ratio | 33.21 |
Dividend yield | 2.74% |
Last dividend (FY23) | $8.52 |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
29 Analysts have issued a Amgen forecast:
29 Analysts have issued a Amgen forecast:
Dec '23 | |
Current assets | 30,332 30,332 |
Fixed assets | 66,822 66,822 |
Total Assets | 97,154 97,154 |
Dec '23 | |
Equity | 6,232 6,232 |
Debt capital | 90,922 90,922 |
Total Capital | 97,154 97,154 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Head office | United States |
CEO | Robert Bradway |
Employees | 26,700 |
Founded | 1980 |
Website | www.amgen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.